The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.
Written by:
Moul JW, Dawson N. Are you the author?
Division of Urologic Surgery and Duke Prostate Center, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Reference: Cancer Invest. 2012 Jan;30(1):1-12.
doi: 10.3109/07357907.2011.629381
PubMed Abstract
PMID: 22236184
UroToday.com Prostate Cancer Section
